Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-armed, Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

NCT05961111 is registered in ClinicalTrials.gov with Shanghai Yunying Medical Technology as lead sponsor.

NCT NCT05961111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05961111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-armed, Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Lead sponsor
Shanghai Yunying Medical Technology
Phase
Phase 1
Overall status
Unknown status
Start date
June 24, 2023
Completion date
June 30, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, breast cancer, carcinoma, digestive cancer, gynecologic cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, sarcoma